Upfront Briefing
Novartis closed its ~$12B Avidity buyout ($72/share cash), and the Atrium Therapeutics spinout launched with ~$270M cash to pursue rare genetic cardiomyopathy RNA programs.
Catalysts: Ascendis won FDA accelerated approval for once-weekly YUVIWEL in achondroplasia (launch expected early Q2; EU decision pending). Clinical tape: Roche reported a third positive Phase 3 for fenebrutinib in MS. IPO tape: Generate:Biomedicines’ $400M IPO finished day 1 down ~21% vs issue.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 (SPY) |
685.99 |
(1.0%) |
+0.6% |
| Nasdaq 100 (QQQ) |
607.29 |
(1.2%) |
(1.1%) |
| Russell 2000 (IWM) |
261.41 |
(1.6%) |
+8.0% |
| Healthcare (XLV) |
160.20 |
+1.1% |
+3.5% |
| Biotech (XBI) |
127.37 |
+1.7% |
+4.5% |
| Nasdaq Biotech (IBB) |
175.37 |
+0.4% |
+3.0% |
| Clinical Trials (BBC) |
42.47 |
+1.5% |
+10.1% |
|
-
Risk-off in growth/small caps: QQQ (-1.2%) and IWM (-1.6%) sold off, consistent with a de-risk / duration-reset tape into month-end.
-
Healthcare led on defense: XLV (+1.1%) outperformed, while biotech showed relative resilience — XBI (+1.7%) bounced with stock-specific catalysts, and “early data” exposure (BBC +1.5%) stayed bid.
The Big 3
|
1
|
Novartis closes Avidity deal as Atrium spinout launches
|
- Novartis closed its ~$12B all-cash buyout of Avidity ($72/share). Atrium Therapeutics spun out with ~$270M cash to advance RNA drugs for rare genetic cardiomyopathies (first IND expected 2H26).
-
Why it matters:
For Novartis, closing Avidity is a clean “pay cash, own the modality” move that locks in late-stage xRNA capacity and removes execution overhang. Atrium is the investor call-option: a well-capitalized NewCo with a specific RNA cardiomyopathy focus — watch (i) first IND timing (2H26), (ii) whether the platform attracts external capital/partners, and (iii) how quickly proof-of-concept can be generated to create a stand-alone valuation anchor.
- Source: Endpoints
- More: BioPharma Dive; Novartis; PR
|
|
2
|
Ascendis wins FDA approval for once-weekly YUVIWEL
|
- Ascendis won FDA accelerated approval for once-weekly YUVIWEL (navepegritide; TransCon CNP) in children with achondroplasia aged 2+. Approval also came with a rare pediatric disease priority review voucher; U.S. launch is expected early Q2 2026 (EU pending).
-
Why it matters:
Weekly TransCon CNP is a direct convenience/continuity challenge to the daily standard of care (BioMarin’s Voxzogo), so the commercial slope hinges on real-world adherence + payer positioning. The PRV is a monetizable asset (non-dilutive capital lever), while accelerated approval keeps a “confirmatory study / label durability” watch-item on the risk register — key next catalysts are early launch uptake and EU timing to shape the global peak curve.
-
Source:
Endpoints
-
More:
PR
|
| 3 | Roche says fenebrutinib hits mark in 3rd Phase 3 MS study |
-
Roche reported a third positive Phase III study for fenebrutinib in multiple sclerosis (FENhance 1). The company said the drug has potential in relapsing and primary progressive MS.
-
Why it matters:
BTK inhibitors in MS have been a “show-me” class after mixed efficacy and safety noise elsewhere; a third positive Phase 3 readout materially compresses the probability-of-success discount and supports an RMS filing sequence. The bigger strategic prize is PPMS differentiation — Roche is running the only PPMS BTKi head-to-head vs Ocrevus, so the investable question is whether efficacy holds with a clean liver-safety profile and produces a defensible label that can expand the franchise beyond CD20.
-
Source:
PR
|
Everything Else that broke
- EMA CHMP backs Moderna flu-COVID combo; other nods follow. — BioPharma Dive
- US ITC opens probe into Chinese state support and biotech. — BioCentury
- Padcev-Keytruda combo posts more positive bladder cancer data. — Endpoints
- Merck seeks Welireg label expansion after combo readouts. — Endpoints
- Novartis, Takeda to enter next Medicare price talks. — Endpoints
- Merck to wind down Gardasil output at N.C. plant, cut 150+. — Spectrum News
- BioNTech advances DualityBio B7-H3 ADC into Phase 3 (736 pts) in mCRPC. — ClinicalTrials.gov
- FDA proposes bonus payments for faster drug reviews. — BioSpace
- States challenge new CDC vaccine schedule, clouding strategy. — BioSpace
- Boehringer wins lung cancer approval under priority program. — BioSpace
- NVIDIA and Lilly launch AI co-innovation lab to reinvent drug discovery. — NVIDIA
- UniQure falls further after Makary comments. — BioPharma Dive
- Sanofi's rilzabrutinib wins Japan orphan designation in IgG4. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Kairos Pharma (KAPA) enters binding terms to acquire CL-273 (AI-designed pan-EGFR inhibitor) from OrbiMed / Torrey Pines-backed Celyn Therapeutics. —
Business Wire
- VERAXA shareholders approve merger with Voyager Acquisition. — PR
- Tevogen signs LOI to evaluate potential acquisition of a CRO. — PR
VC / Private Financings
-
OutPost Bio: €2.9M pre-Seed — co-led by Merantix Capital and Seedcamp; joined by OpenSeed VC and Defined (plus angels/family offices). —
EU-Startups
-
Zymeworks: $250M royalty-backed note financing with Royalty Pharma (repayment from 30% of worldwide tiered royalties on Ziihera until repaid). —
PR
-
BreezeBio (ex-GenEdit): $60M Series B — co-led by Yuanta Investment and DSC Investment; joined by SV Investment, Kiwoom Investment, STIC Ventures, and Dayli Partners. —
PR
-
Atrium Therapeutics launches (Avidity separation) with ~$270M cash; first IND expected 2H26. —
PR
IPOs / Follow-Ons
-
Generate:Biomedicines raises $400M IPO at $16; closed day 1 at $12.65 (~-21%). —
GEN;
Company
Academic Corner - A small-molecule inverse agonist of PPARb3 for advanced solid tumors: a phase 1 trial. — Nature Medicine
|
